Profile data is unavailable for this security.
About the company
89bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. The Company’s lead product candidate, pegozafermin, a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG). Pegozafermin is engineered to protect against proteolysis and reduce renal clearance and optimize its potency, enabling the potential use of a lower dosage/dose. Pegozafermin has been optimally constructed with two mutations via substitutions with natural amino acids at site-specific positions (173 and 176) toward the C-terminus end of the hormone. It conducted a Phase I clinical trial to evaluate the safety, tolerability and pharmacokinetics (PK) of pegozafermin.
- Revenue in USD (TTM)0.00
- Net income in USD-165.03m
- Incorporated2019
- Employees70.00
- Location89Bio Inc142 Sansome Street, Second FloorSan Francisco 94104United StatesUSA
- Phone+1 (415) 432-9270
- Fax+1 (302) 655-5049
- Websitehttps://www.89bio.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Rapport Therapeutics Inc | 0.00 | -51.31m | 843.09m | 58.00 | -- | -- | -- | -- | -1.45 | -1.45 | 0.00 | 5.52 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -226.57 | -- | -- | -- |
| Dianthus Therapeutics Inc | 3.22m | -50.21m | 850.25m | 53.00 | -- | 2.28 | -- | 263.73 | -3.20 | -3.20 | 0.2721 | 12.70 | 0.0138 | -- | -- | 60,830.19 | -21.56 | -41.40 | -22.27 | -44.70 | -- | -- | -1,557.51 | -12,132.27 | -- | -- | 0.00 | -- | -- | -- | 43.04 | -- | -57.21 | -- |
| Olema Pharmaceuticals Inc | 0.00 | -99.34m | 863.06m | 75.00 | -- | 3.65 | -- | -- | -2.02 | -2.02 | 0.00 | 4.23 | 0.00 | -- | -- | 0.00 | -43.24 | -30.06 | -48.01 | -31.40 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 7.76 | -- | -- | -- |
| Lexicon Pharmaceuticals Inc | 2.31m | -193.58m | 863.85m | 285.00 | -- | 2.04 | -- | 373.80 | -0.8257 | -0.8257 | 0.0098 | 1.17 | 0.008 | -- | 2.59 | 8,108.77 | -66.76 | -24.41 | -72.21 | -29.01 | 94.98 | 98.49 | -8,376.55 | -84.92 | 15.56 | -11.46 | 0.2569 | -- | 766.19 | -54.71 | -73.74 | -- | 37.68 | -- |
| 89bio Inc | 0.00 | -165.03m | 909.07m | 70.00 | -- | 1.72 | -- | -- | -2.01 | -2.01 | 0.00 | 5.36 | 0.00 | -- | -- | 0.00 | -30.80 | -45.50 | -32.70 | -49.31 | -- | -- | -- | -- | -- | -- | 0.0466 | -- | -- | -- | -39.37 | -- | -36.58 | -- |
| Cogent Biosciences Inc | 0.00 | -212.17m | 910.24m | 164.00 | -- | 4.55 | -- | -- | -2.47 | -2.47 | 0.00 | 4.42 | 0.00 | -- | -- | 0.00 | -57.40 | -49.53 | -62.27 | -54.94 | -- | -- | -- | -1,684.44 | -- | -- | 0.00 | -- | -- | -- | -37.20 | -- | 38.48 | -- |
| Perspective Therapeutics Inc | -304.00k | -48.91m | 923.08m | 116.00 | -- | 3.50 | -- | -- | -1.62 | -1.97 | -0.0092 | 3.92 | -0.0015 | -- | -- | -2,620.69 | -24.10 | -- | -25.46 | -- | -- | -- | -- | -- | -- | -- | 0.0074 | -- | -- | -- | -- | -- | -- | -- |
| Nuvation Bio Inc | 0.00 | -68.87m | 924.42m | 159.00 | -- | 1.38 | -- | -- | -0.3146 | -0.3146 | 0.00 | 2.71 | 0.00 | -- | -- | 0.00 | -10.84 | -16.27 | -11.09 | -16.65 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 27.25 | -- | -- | -- |
| Pharvaris NV | 0.00 | -115.37m | 936.41m | 82.00 | -- | 2.40 | -- | -- | -2.58 | -2.58 | 0.00 | 7.25 | 0.00 | -- | -- | 0.00 | -40.45 | -36.09 | -43.50 | -38.27 | -- | -- | -- | -- | -- | -127.47 | 0.0005 | -- | -- | -- | -32.15 | -- | -- | -- |
| Humacyte Inc | 0.00 | -105.70m | 945.53m | 183.00 | -- | 36.16 | -- | -- | -1.01 | -1.01 | 0.00 | 0.2196 | 0.00 | -- | -- | 0.00 | -61.38 | -- | -68.92 | -- | -- | -- | -- | -- | -- | -61.50 | 0.4145 | -- | -100.00 | -- | -825.83 | -- | -- | -- |
| 4D Molecular Therapeutics Inc | 20.45m | -104.56m | 948.76m | 171.00 | -- | 1.56 | -- | 46.39 | -2.36 | -2.36 | 0.4841 | 11.74 | 0.0468 | -- | -- | 139,136.00 | -23.93 | -32.67 | -24.71 | -34.90 | -- | -- | -511.20 | -617.15 | -- | -- | 0.00 | -- | 562.29 | 7.96 | 6.19 | -- | 46.26 | -- |
| AbCellera Biologics Inc | 35.79m | -146.90m | 958.62m | 586.00 | -- | 0.8472 | -- | 26.79 | -0.5056 | -0.5056 | 0.1232 | 3.85 | 0.0242 | -- | 1.32 | 61,071.67 | -9.92 | 6.08 | -10.62 | 6.67 | -- | -- | -410.47 | 24.69 | 7.75 | -- | 0.00 | 0.00 | -92.17 | 33.91 | -192.35 | -- | 70.96 | -- |
| Silence Therapeutics plc | 33.99m | -44.97m | 979.39m | 115.00 | -- | 6.17 | -- | 28.81 | -0.3952 | -0.3952 | 0.2886 | 1.14 | 0.1829 | -- | 5.37 | 295,574.70 | -24.20 | -43.60 | -27.21 | -54.91 | 69.72 | -- | -132.31 | -287.30 | -- | -- | 0.0022 | -- | 44.99 | -- | -6.86 | -- | 156.10 | -- |
Data as of Jul 26 2024. Currency figures normalised to 89Bio Inc's reporting currency: US Dollar USD
68.78%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| RA Capital Management LPas of 11 Apr 2024 | 14.18m | 14.41% |
| Janus Henderson Investors US LLCas of 31 Mar 2024 | 12.56m | 12.77% |
| RTW Investments LPas of 31 Mar 2024 | 7.38m | 7.50% |
| Suvretta Capital Management LLCas of 31 Mar 2024 | 6.30m | 6.40% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 5.99m | 6.09% |
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 5.54m | 5.64% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 4.51m | 4.58% |
| BVF Partners LPas of 31 Mar 2024 | 4.05m | 4.11% |
| Pictet Asset Management SAas of 31 Mar 2024 | 3.71m | 3.77% |
| Holocene Advisors, LPas of 31 Mar 2024 | 3.45m | 3.51% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
